PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
Fenbendazole and Prostate Cancer: What Does the Science Really Say? Fenbendazole — often shortened to “fenben” — has gained attention online as a possible alternative cancer therapy. Social media stories often mention dramatic responses in various cancers, including prostate cancer. But what does the scientific research actually show for prostate cancer patients?
I am a long-term survivor of an incurable blood cancer called multiple myeloma. I have gone to great lengths and taken great risks in an effort to manage my blood cancer. I can understand why cancer patients hear about non-conventional therapies and want to understand more about them as possible therapies.
The post below is PeopleBeatingCancer’s effort to weigh in on the fenben and prostate cancer debate. Please scroll down the page, post a question or a comment if you have any questions.
If you’d like to learn more about repurposed drugs and cancer treatment, click now.
Thank you,
Fenbendazole is a veterinary anti-parasitic drug commonly used to treat worm infections in animals. It belongs to the benzimidazole class of drugs, which interfere with microtubules — structural components within cells that are essential for cell division. Because many chemotherapy drugs also target microtubules, researchers have explored whether fenbendazole might have anticancer effects. However:
The U.S. Food and Drug Administration (FDA) has not approved fenbendazole for treating any cancer type. In fact, some people who self-administer it have experienced serious toxicity, including liver injury.
Interest in fenbendazole for cancer stems from several laboratory findings suggesting possible mechanisms:
However, a plausible mechanism in the lab does not equal proven clinical benefit in humans.
Most evidence for fenbendazole and prostate cancer comes from preclinical studies:
But it’s important to understand:
These laboratory findings are preliminary. Preclinical studies do not prove that a drug treats prostate cancer in humans.
There are no large, controlled clinical trials showing that fenbendazole is safe and effective for prostate cancer. There are also no guideline recommendations supporting its use, and human safety data are extremely limited.
Because fenbendazole is formulated for animals:
Using unproven substances can also delay or interfere with effective therapy, potentially worsening outcomes.
Many compounds that look promising in cell and animal models:
The vast majority of agents tested in preclinical cancer research never become approved cancer treatments.
Here is the balanced conclusion:
At this time, fenbendazole remains an experimental, unproven approach — not an evidence-based prostate cancer therapy.
Before making any decision:
Cancer treatment decisions should be guided by evidence, safety, and long-term outcomes — not internet testimonials.
PMC
ScienceDirect
American Cancer Society
PubMed
CancerChoices
Fenbendazole and Prostate Cancer Fenbendazole and Prostate Cancer Fenbendazole and Prostate Cancer